[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525057":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":36,"centralContacts":40,"locations":46,"responsibleParty":191,"collaborators":26,"id":193,"slug":194,"hasResults":195,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":26,"eligibilityCriteria":199,"healthyVolunteers":195,"sex":200,"minAge":201,"maxAge":26,"enrollmentInfo":202,"targetDuration":26,"studyType":205,"phases":206,"briefSummary":208,"conditions":209,"keywords":26,"overallStatus":49,"whyStopped":26,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},{"fullName":5,"class":6},"Johnson & Johnson Enterprise Innovation Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: JNJ-86974680+Cetrelimab","EXPERIMENTAL","Participants will receive JNJ-86974680 alone (dose 1, dose 2, dose 3, and dose 4) daily in 4 cohorts and then along with a set dose of cetrelimab.",[13,14],"Drug: JNJ-86974680","Drug: Cetrelimab",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 2: JNJ-86974680+Cetrelimab+Radiation Therapy (RT)","Part 2 will consist of 3 cohorts (A, B and C) and participants will receive treatment with the selected dose of JNJ-86974680 in combination with cetrelimab from part 1, in conjunction with radiation.",[13,14,19],"Radiation: Radiation Therapy",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","JNJ-86974680","JNJ-86974680 will be administered.",[9,16],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Cetrelimab","Cetrelimab will be administered.",[9,16],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":26},"RADIATION","Radiation Therapy","Radiation therapy will be administered.",[16],[37],{"name":38,"affiliation":5,"role":39},"Johnson & Johnson Enterprise Innovation, Inc Clinical Trial","STUDY_DIRECTOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":26,"email":45},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[47,61,71,81,89,99,109,119,131,140,150,156,167,173,182],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":26},"City of Hope 1","RECRUITING","Newnan","Georgia","30265","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-84.79966,33.38067,{"lat":59,"lon":58},{"facility":62,"status":49,"city":63,"state":64,"zip":65,"country":53,"countryCode":54,"cosmosGeoPoint":66,"geoPoint":70,"contacts":26},"Hackensack University Medical Center","Hackensack","New Jersey","07601",{"type":56,"coordinates":67},[68,69],-74.04347,40.88593,{"lat":69,"lon":68},{"facility":72,"status":49,"city":73,"state":74,"zip":75,"country":53,"countryCode":54,"cosmosGeoPoint":76,"geoPoint":80,"contacts":26},"Roswell Park Comprehensive Cancer Center","Buffalo","New York","14203",{"type":56,"coordinates":77},[78,79],-78.87837,42.88645,{"lat":79,"lon":78},{"facility":82,"status":49,"city":74,"state":74,"zip":83,"country":53,"countryCode":54,"cosmosGeoPoint":84,"geoPoint":88,"contacts":26},"Herbert Irving Comprehensive Cancer Center Columbia University Medical Center","10032",{"type":56,"coordinates":85},[86,87],-74.00597,40.71427,{"lat":87,"lon":86},{"facility":90,"status":49,"city":91,"state":92,"zip":93,"country":53,"countryCode":54,"cosmosGeoPoint":94,"geoPoint":98,"contacts":26},"Providence Portland Medical Center","Portland","Oregon","97213",{"type":56,"coordinates":95},[96,97],-122.67621,45.52345,{"lat":97,"lon":96},{"facility":100,"status":49,"city":101,"state":102,"zip":103,"country":53,"countryCode":54,"cosmosGeoPoint":104,"geoPoint":108,"contacts":26},"Thomas Jefferson University","Philadelphia","Pennsylvania","19107",{"type":56,"coordinates":105},[106,107],-75.16362,39.95238,{"lat":107,"lon":106},{"facility":110,"status":49,"city":111,"state":112,"zip":113,"country":53,"countryCode":54,"cosmosGeoPoint":114,"geoPoint":118,"contacts":26},"Next Virginia","Fairfax","Virginia","22031",{"type":56,"coordinates":115},[116,117],-77.30637,38.84622,{"lat":117,"lon":116},{"facility":120,"status":121,"city":122,"state":26,"zip":123,"country":124,"countryCode":125,"cosmosGeoPoint":126,"geoPoint":130,"contacts":26},"Charite Research Organisation GmbH","COMPLETED","Berlin","12203","Germany","DE",{"type":56,"coordinates":127},[128,129],13.41053,52.52437,{"lat":129,"lon":128},{"facility":132,"status":49,"city":133,"state":26,"zip":134,"country":124,"countryCode":125,"cosmosGeoPoint":135,"geoPoint":139,"contacts":26},"Universitaetsklinikum Giessen und Marburg GmbH","Giessen","35392",{"type":56,"coordinates":136},[137,138],8.67554,50.58727,{"lat":138,"lon":137},{"facility":141,"status":49,"city":142,"state":26,"zip":143,"country":144,"countryCode":26,"cosmosGeoPoint":145,"geoPoint":149,"contacts":26},"Severance Hospital Yonsei University Health System","Seoul","03722","South Korea",{"type":56,"coordinates":146},[147,148],126.9784,37.566,{"lat":148,"lon":147},{"facility":151,"status":49,"city":142,"state":26,"zip":152,"country":144,"countryCode":26,"cosmosGeoPoint":153,"geoPoint":155,"contacts":26},"Samsung Medical Center","06351",{"type":56,"coordinates":154},[147,148],{"lat":148,"lon":147},{"facility":157,"status":49,"city":158,"state":26,"zip":159,"country":160,"countryCode":161,"cosmosGeoPoint":162,"geoPoint":166,"contacts":26},"Hosp. Univ. Quiron Dexeus","Barcelona","08028","Spain","ES",{"type":56,"coordinates":163},[164,165],2.15899,41.38879,{"lat":165,"lon":164},{"facility":168,"status":49,"city":158,"state":26,"zip":169,"country":160,"countryCode":161,"cosmosGeoPoint":170,"geoPoint":172,"contacts":26},"Hosp Univ Vall D Hebron","8035",{"type":56,"coordinates":171},[164,165],{"lat":165,"lon":164},{"facility":174,"status":49,"city":175,"state":26,"zip":176,"country":160,"countryCode":161,"cosmosGeoPoint":177,"geoPoint":181,"contacts":26},"Hosp. Univ. 12 de Octubre","Madrid","28041",{"type":56,"coordinates":178},[179,180],-3.70256,40.4165,{"lat":180,"lon":179},{"facility":183,"status":49,"city":184,"state":26,"zip":185,"country":160,"countryCode":161,"cosmosGeoPoint":186,"geoPoint":190,"contacts":26},"Hosp. Univ. I Politecni La Fe","Valencia","46026",{"type":56,"coordinates":187},[188,189],-0.37966,39.47391,{"lat":189,"lon":188},{"type":192,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100525057","phase-1-a-study-of-jnj-86974680-in-participants-with-advanced-non-small-cell-lung-cancer-100525057",false,"NCT06116786","A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer","A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)\n* Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \\[EGFR\\], anaplastic lymphoma kinase \\[ALK\\], c-ros oncogene 1 \\[ROS1\\], v-raf murine sarcoma viral oncogene homolog B1 \\[BRAF\\]) must have received all approved targeted therapies and have progressed\n* Part 2: No targetable mutations (for example, EGFR \\[epidermal growth factor receptor\\], ALK \\[anaplastic lymphoma kinase\\], ROS1\\[c-ros oncogene 1\\], and BRAF \\[B-Raf proto-oncogene, serine\u002Fthreonine kinase\\])\n* Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy\n* For Cohort B of Part 2: Previously treated with anti-PD-1\u002FPD-L1 therapy for metastatic disease as the prior line of therapy\n* For Cohort C of Part 2: Treatment naïve\n* Adequate organ function\n\nExclusion Criteria:\n\n* Active central nervous system (CNS) disease involvement\n* Active autoimmune disease\n* Active infection\n* History of solid organ or hematologic stem cell transplantation","ALL","18 Years",{"count":203,"type":204},126,"ESTIMATED","INTERVENTIONAL",[207],"PHASE1","The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.",[210],"Carcinoma, Non-small-Cell Lung","2026-06-19",{"date":213,"type":214},"2026-06-24","ACTUAL",{"date":216,"type":214},"2023-11-27",{"date":218,"type":204},"2029-06-07",{"name":5,"class":6},15]